ข้อมูลเทคโนโลยีที่ใช้ในการผลิต

ข้อมูลเทคโนโลยีที่ใช้ในการผลิต

-
Draft Cell and Gene Therapy Guidance Document Calls for Comparability and Lifecycle Management
-
Food & Drug Administration (FDA) guidance is just now addressing the challenges of manufacturing cell and gene therapy (CGT) products with a proposed draft guidance, Manufacturing Changes and Comparability for Human Cellular and Gene Therapy Products. The draft guidance outlines a lifecycle approach to managing and reporting manufacturing changes, as well as robust comparability studies to determine the effects of such changes (including transferring manufacturing to new facilities) on product quality. The comment period ends September 12,2023. “Managing changes to manufacturing processes has been a common roadblock for many CGT companies to navigate, particularly given that manufacturing challenges have been pervasive in this industry,” Stacy Cline Amin, leader of the FDA, healthcare regulatory and compliance practice at Morrison Foerster, tells GEN. “CGT companies have been frustrated with written-response-only meetings and the lack of informal opportunities to consult with the agency. This guidance should reduce some of the uncertainties CGT sponsors face and help facilitate more meaningful discussions between FDA and industry on some of these nuanced quality issues.”
-
-
-
0